KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Pregnancy Could Help Reduce the Risk of Long COVID April 2, 2025A study found that patients who acquired a SARS-CoV-2 infection during pregnancy had a lower risk of developing long COVID compared to those who were not pregnant.
- Allergic Contact Dermatitis Remains Prevalent, Negatively Impacts Quality of Life April 2, 2025Researchers conducted a comprehensive review of allergic contact dermatitis, detailing the condition’s epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic options.
- Virtual Self-Management Tools Can Reduce Blood Sugar in Type 2 Diabetes April 2, 2025All 3 types of virtual diabetes self-management interventions lead to better results in hemoglobin A1c over a 6-month period.
- Media Coverage, Local Outbreaks Changing Views on Vaccine Hesitancy April 2, 2025A HealthDay Harris Poll highlights the most recent feelings patients have towards vaccines amid outbreaks of vaccine-preventable illness and changes at the federal level impacting public health policy.
- Glucocorticoids May Reduce Mortality for Community-Acquired Pneumonia April 2, 2025Glucocorticoid use for severe community-acquired pneumonia has been controversial due to the safety profile of these drugs.
- Effects of Long COVID on Heart Health Remain Unknown April 2, 2025Pharmacists can help manage complications from long COVID-19, as no medications can treat it.
- Q&A: CGMs Empower Patients to Take Control of Diabetes Care | APhA 2025 April 2, 2025The integration of CGM into pharmacy practice represents a significant opportunity for pharmacists to provide enhanced patient care.
- Sotatercept Reduces Risk of Major Morbidity, Mortality for Pulmonary Arterial Hypertension April 2, 2025Patients with pulmonary arterial hypertension (PAH) received the maximum tolerated dose of background therapy with sotatercept or the placebo to the therapy.
- Dispensing Leadership: Philosophies for Teamwork April 1, 2025In this episode of the podcast, Shawn and Jesse outline 3 key principles about teamwork that can drive success in the pharmacy.
- Procedure Helps Prevent Weight Regain After Discontinuation of GLP-1 Medication April 1, 2025The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.
Pharmacy Times articles
- The GLP-1 Conundrum: Insights from the 2025 Pharmacy in Focus Report April 2, 2025Pharmacists play a crucial role in educating patients on proper administration and adherence to GLP-1 treatments.
- ELCC 2025: Amivantamab Plus Lazertinib Effective in EGFR-Mutated NSCLC Versus Standard of Care April 2, 2025Nicolas Girard, MD, explains the benefits observed in the MARIPOSA clinical trial among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with amivantamab plus lazertinib.
- Single Dose of PCV20 for Toddlers Following Previous PCV13 Doses Protects Against Additional Pneumococcal Serotypes April 2, 2025These new phase 3 results indicate the effectiveness of the 2-dose 13-valent pneumococcal conjugate vaccine (PCV13) and 1-dose PCV20 regimens.
- Understand the 2025-2026 Flu Vaccine Composition Recommendations April 2, 2025The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.
- Revolutionizing Treatment with Bispecific Therapies: Navigating the Challenges Ahead April 2, 2025By decade’s end, approval of additional bispecifics is expected for hematological malignancies, solid tumors, and non-oncology conditions such as inflammatory, autoimmune, neurodegenerative and vascular diseases, and ocular disorders and infections.
- The Use of CMR in Patients With Recurrent Pericarditis Initiating Rilonacept April 2, 2025The registry data showed that cardiac magnetic resonance (CMR) was obtained in more clinically complex patients with recurrent pericarditis.
- FDA Approves Auto-Pure 2400 for Faster, More Accurate Tuberculosis Diagnosis April 2, 2025The Auto-Pure 2400 system combines liquid handling and magnetic cell isolation for efficient latent tuberculosis testing.
- Pharmacist-Driven Management of Venetoclax Ramp-Up Safe, Feasible in Patients With Chronic Lymphocytic Leukemia April 2, 2025Pharmacists performed weekly toxicity and tumor lysis syndrome monitoring.
- The Future of the Protecting Pharmacies in Medicaid Act Requires Advocacy April 2, 2025Similar legislation could also address PBM practices in commercial insurance.
- How Pharmacies Can Better Support Employees Living with Serious Mental Illness April 2, 2025Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com